Psoriasis severity in moderate to severe psoriatic Greek patients routinely treated with systemic treatment: a cross-sectional and retrospective chart review study (CRYSTAL-Greece)

• Published in: The Journal of dermatological treatment 2025-12, Vol.36 (1), p.2402344
• Main Authors: Rigopoulos, Dimitrios, Katsantonis, J, Neofotistou, O, Chasapi, V, Lazaridou, E, Roussaki-Schulze, A V, Papakonstantis, M, Angelakopoulos, C, Rigatos, P, Aronis, P, Zeglinas, C, Kyriakakis, A, Heatta-Speicher, T, Kollia, A, Antachopoulou, K, Papadavid, E
• Format: Article
• Language: English
• Subjects: Absolute PASI; Adolescent; Adult; Aged; Biological Products - therapeutic use; Cross-Sectional Studies; Dermatologic Agents - therapeutic use; DLQI; Female; Greece; Humans; Male; Middle Aged; moderate-to-severe psoriasis; Psoriasis - drug therapy; Psoriasis - pathology; Quality of Life; real-world; Retrospective Studies; Severity of Illness Index; systemic treatment; Treatment Outcome; Young Adult
• ISSN: 0954-6634; 1471-1753; 1471-1753
• DOI: 10.1080/09546634.2024.2402344

To characterize the systemic treatment patterns and current state of moderate-to-severe psoriasis patients in real-world settings in Greece. CRYSTAL-Greece was a multicenter, cross-sectional and retrospective chart review study assessing Psoriasis Area and Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol-5-Dimensions 5-Levels (EQ-5D-5L). Eligible patients were consented adults (18-75 years old) on continuous treatment with any approved systemic therapy regimen for ≥24 weeks. 280 eligible patients were enrolled between 07APR2020 and 30NOV2020. Current treatment at the study visit was biologic monotherapy in 78.2% of patients, non-biologic monotherapy in 16.1%, and conventional systemic + biologic in 5.7%. Median absolute PASI score was 1.8; of patients, 36.8%/64.6%/83.9% had PASI ≤ 1/≤3/≤5. Rates of absolute PASI > 5 were 13.7% and 28.9% in the biologic and non-biologic monotherapy subgroups, respectively. Median DLQI score was 2.0, with 18.9% of patients having DLQI > 5 (16.0% and 26.7% in the biologic and non-biologic monotherapy subgroups, respectively). The correlation between DLQI and absolute PASI was low positive (Spearman rho = 0.432;